Predictive value of serum alanine aminotransferase for fatty liver associated with metabolic dysfunction  

作　　者：Wen-Xiu Liu Lei Liu 

机构地区：[1]State Key Laboratory of Oral Diseases,National Center for Stomatology,National Clinical Research Center for Oral Diseases,Department of Oral and Maxillofacial Surgery,West China Hospital of Stomatology,Sichuan University,Chengdu 610041,Sichuan Province,China

出　　处：《World Journal of Hepatology》2024年第7期990-994,共5页世界肝病学杂志（英文版）（电子版）

基　　金：Supported by the Natural Science Foundation of Sichuan Province,No.24NSFSC0163;State Key Clinical Department of Oral&Maxillofacial Surgery。

摘　　要：In this editorial,we offer commentary on the article published by Chen et al in a recent issue of the World Journal of Gastroenterology(2024;30:1346-1357).The study highlights a noteworthy association between persistently elevated,yet highnormal levels of alanine transaminase(ALT)and an escalated cumulative risk of developing metabolic dysfunction-associated fatty liver disease(MAFLD).MAFLD has emerged as a globally prevalent chronic liver condition,whose incidence is steadily rising in parallel with improvements in living standards.Left unchecked,MAFLD can progress from hepatic steatosis to liver fibrosis,cirrhosis,and even hepatocellular carcinoma,underscoring the importance of early screening and diagnosis.ALT is widely recognized as a reliable biomarker for assessing the extent of hepatocellular damage.While ALT levels demonstrate a significant correlation with the severity of fatty liver disease,they lack specificity.The article by Chen et al contributes to our understanding of the development of MAFLD by investigating the long-term implications of high-normal ALT levels.Their findings suggest that sustained elevation within the normal range is linked to an increased likelihood of developing MAFLD,emphasizing the need for closer monitoring and potential intervention in such cases.

关 键 词：Metabolic dysfunction-associated fatty liver disease Alanine aminotransferase Upper reference limits FIBROSIS Metabolic dysfunction-associated steatohepatitis CIRRHOSIS 

分 类 号：R575.5[医药卫生—消化系统]